Fibrobiologics, Common Stock Stock Performance
| FBLG Stock | 2.56 0.09 3.64% |
FibroBiologics, Common holds a performance score of 9 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 2.98, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, FibroBiologics, Common will likely underperform. Use FibroBiologics, Common treynor ratio, expected short fall, and the relationship between the jensen alpha and potential upside , to analyze future returns on FibroBiologics, Common.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in FibroBiologics, Common Stock are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak essential indicators, FibroBiologics, Common reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.64 | Five Day Return 6.22 | Year To Date Return (91.20) | Ten Year Return (91.20) | All Time Return (91.20) |
1 | FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology | 09/12/2024 |
2 | FibroBiologics to Present at 2024 Cell Gene Meeting on the Mesa | 09/30/2024 |
3 | FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office | 10/16/2024 |
4 | FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology | 10/29/2024 |
5 | FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction in Cell-Based Therapeutic... | 11/14/2024 |
6 | FBLG On Target to Initiate Phase 12 Trial in 2025 | 11/21/2024 |
| Begin Period Cash Flow | 2.3 M |
FibroBiologics, |
FibroBiologics, Common Relative Risk vs. Return Landscape
If you would invest 162.00 in FibroBiologics, Common Stock on August 30, 2024 and sell it today you would earn a total of 94.00 from holding FibroBiologics, Common Stock or generate 58.02% return on investment over 90 days. FibroBiologics, Common Stock is currently generating 1.1805% in daily expected returns and assumes 10.13% risk (volatility on return distribution) over the 90 days horizon. In different words, 90% of stocks are less volatile than FibroBiologics,, and 77% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
FibroBiologics, Common Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for FibroBiologics, Common's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as FibroBiologics, Common Stock, and traders can use it to determine the average amount a FibroBiologics, Common's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1165
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | FBLG | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.13 actual daily | 90 90% of assets are less volatile |
Expected Return
| 1.18 actual daily | 23 77% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average FibroBiologics, Common is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of FibroBiologics, Common by adding it to a well-diversified portfolio.
FibroBiologics, Common Fundamentals Growth
FibroBiologics, Stock prices reflect investors' perceptions of the future prospects and financial health of FibroBiologics, Common, and FibroBiologics, Common fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on FibroBiologics, Stock performance.
| Return On Equity | -4.34 | ||||
| Return On Asset | -0.62 | ||||
| Current Valuation | 110.48 M | ||||
| Shares Outstanding | 35.26 M | ||||
| Price To Book | 300.03 X | ||||
| EBITDA | (15.9 M) | ||||
| Net Income | (16.48 M) | ||||
| Total Debt | 1.75 M | ||||
| Book Value Per Share | (0.07) X | ||||
| Cash Flow From Operations | (6.4 M) | ||||
| Earnings Per Share | (0.59) X | ||||
| Market Capitalization | 114.94 M | ||||
| Total Asset | 11.82 M | ||||
| Retained Earnings | (24.36 M) | ||||
| Working Capital | 32 K | ||||
About FibroBiologics, Common Performance
By analyzing FibroBiologics, Common's fundamental ratios, stakeholders can gain valuable insights into FibroBiologics, Common's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if FibroBiologics, Common has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if FibroBiologics, Common has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.39) | (1.46) | |
| Return On Capital Employed | (3.37) | (3.20) | |
| Return On Assets | (1.39) | (1.46) | |
| Return On Equity | (13.16) | (12.50) |
Things to note about FibroBiologics, Common performance evaluation
Checking the ongoing alerts about FibroBiologics, Common for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for FibroBiologics, Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| FibroBiologics, Common is way too risky over 90 days horizon | |
| FibroBiologics, Common appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (16.48 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| FibroBiologics, Common generates negative cash flow from operations | |
| FibroBiologics, Common has a poor financial position based on the latest SEC disclosures | |
| About 28.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: FBLG On Target to Initiate Phase 12 Trial in 2025 |
- Analyzing FibroBiologics, Common's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether FibroBiologics, Common's stock is overvalued or undervalued compared to its peers.
- Examining FibroBiologics, Common's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating FibroBiologics, Common's management team can have a significant impact on its success or failure. Reviewing the track record and experience of FibroBiologics, Common's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of FibroBiologics, Common's stock. These opinions can provide insight into FibroBiologics, Common's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for FibroBiologics, Stock analysis
When running FibroBiologics, Common's price analysis, check to measure FibroBiologics, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroBiologics, Common is operating at the current time. Most of FibroBiologics, Common's value examination focuses on studying past and present price action to predict the probability of FibroBiologics, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroBiologics, Common's price. Additionally, you may evaluate how the addition of FibroBiologics, Common to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |